Saba Radhi
Expertise in
12
conditions

Dr. Saba Radhi

Otolaryngology | Hematology Oncology | Oncology
2946 East Banner Gateway Drive, 
Gilbert, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
2946 East Banner Gateway Drive, 
Gilbert, AZ 

Overview

I enjoy taking strolls in nature and yoga.

Dr. Radhi is highly rated in 12 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, Gastrointestinal Stromal Tumor, and Endoscopy.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Sultan Qaboos University, 2000

Residency

Texas Tech University Health Science Center-IM, Internal Medicine, 2010

Specialties

Otolaryngology
Hematology Oncology
Oncology

Licenses

Internal Medicine in TX

Board Certifications

American Board Of Internal Medicine/Medical Oncology

Fellowships

Texas Tech University Health Science Center-IM, Geriatric Medicine, 2011
Texas Tech University Health Science Center-IM, Medical Oncology, 2013

Hospital Affiliations

Banner Gateway Medical Center

Languages Spoken

English
Arabic

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Banner MD Anderson Cancer Center at Banner Gateway Medical Center
2946 East Banner Gateway Drive, Gilbert, AZ 85234
Other Locations
Banner MD Anderson Cancer Center at Banner University Medical Center - Phoenix
925 East McDowell Road, Phoenix, AZ 85006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
View 7 Less Clinical Trials

8 Total Publications

Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
Journal: Progress in molecular biology and translational science
Published: November 21, 2016
Similar Doctors
Jason Niu
Expertise in
30
conditions
Dr. Jason Niu
Oncology | Hematology | Otolaryngology
Expertise in
30
conditions
Dr. Jason Niu
Oncology | Hematology | Otolaryngology

Banner MD Anderson Cancer Center At Banner Gateway Medical Center

2946 East Banner Gateway Drive, 
Gilbert, AZ 
 (1.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy running, playing tennis and gardening. Dr. Niu is highly rated in 30 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

Matthew Ulrickson
Expertise in
30
conditions
Dr. Matthew Ulrickson
Hematology Oncology | Transplant Surgery
Expertise in
30
conditions
Dr. Matthew Ulrickson
Hematology Oncology | Transplant Surgery

Banner MD Anderson Cancer Center At Banner Gateway Medical Center

2946 East Banner Gateway Drive, 
Gilbert, AZ 
 (1.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I am an Arizona native and enjoy swimming and the outdoors, as well as spending time with my wife and children. I also have a special interest in improving the care of cancer patients in sub-Saharan Africa. Dr. Ulrickson is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

David Paul
Expertise in
35
conditions
Dr. David Paul
Hematology Oncology | Oncology
Expertise in
35
conditions
Dr. David Paul
Hematology Oncology | Oncology

Banner MD Anderson Cancer Center At Banner University Medical Center - Phoenix

925 East McDowell Road, 
Phoenix, AZ 
 (20.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy golf, tennis and spending time with family. Dr. Paul is highly rated in 35 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Saba Radhi

How do I make an appointment with Dr. Saba Radhi?

You can book an appointment with Dr. Saba Radhi by calling their office at 480-256-6444. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Saba Radhi a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Saba Radhi is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Saba Radhi specialize in?

While Dr. Saba Radhi is a Otolaryngology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Otolaryngology.

Does Dr. Saba Radhi participate in research or clinical trials?

Yes. Dr. Saba Radhi has published 8 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Saba Radhi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Saba Radhi accept my insurance?

Dr. Saba Radhi accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 480-256-6444 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Radhi's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile